Biotech - Spark Newswire

2 minute read

BridgeBio’s Dwarfism Candidate Shows Favorable Height Increase, Safety Profile

Today, 7:01 PM

BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the fibroblast growth factor receptor.

BBIO

1 minute read

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer’s Treatment

By Vandana Singh

Today, 7:01 PM

The FDA has accepted Eisai Co Ltd (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection,…

BIIB

4 minute read

New Study Evaluates The Use Of Masimo PVi As An Indicator Of Fluid Responsiveness To Guide Goal-Directed Fluid Therapy In Adult Neurosurgical Patients

By Happy Mohamed

Today, 7:01 PM

Researchers Found That Noninvasive, Continuous PVi Was Equally Effective in Guiding Fluid Management As Stroke Volume Variation (SVV), an Invasive Method Requiring an Arterial Line Masimo (NASDAQ:MASI) today

MASI

1 minute read

Why Unicycive Therapeutics Stock Is Exploding Higher Monday

By Adam Eckert

Today, 7:01 PM

Unicycive Therapeutics Inc (NASDAQ: UNCY) shares are exploding higher Monday after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb, a phosphate binder that potently controls phosphate with just

UNCY

1 minute read

Ra Medical’s Electrophysiology Division Announces First Use Of Catheter Precision’s LockeT Was Successfully Used In Series Of Patients

By Happy Mohamed

Today, 7:01 PM

Catheter Precision's LockeT Successfully Used in Series of Patients FORT MILL, SC / ACCESSWIRE / March 6, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) announced today that its wholly owned subsidiary,

RMED

1 minute read

Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle

By Vandana Singh

Today, 7:01 PM

Cytokinetics Incorporated (NASDAQ:CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At…

CYTK

1 minute read

Esperion Long Term Data On Cholesterol Medication’s Ability To Cut Cardiovascular Risk Fails To Impress Investors

By Vandana Singh

Today, 7:01 PM

Esperion Therapeutics Inc (NASDAQ:ESPR) announced the full results from the CLEAR Outcomes trial, a global study of nearly 14,000 patients with…

ESPR

1 minute read

Immuneering Will Be Presenting Preclinical Data On Its Lead Program IMM-1-104 At American Association For Cancer Research Showing Broad Response Demonstrated Through Deep Cyclic Inhibition Of MAPK Pathway, Independent Of Specific RAS Mutation

By Benzinga Newsdesk

Today, 7:01 PM

Phase 1/2a clinical trial with IMM-1-104 is underway in patients with advanced solid tumors harboring RAS mutations.

IMRX

1 minute read

FDA Accepted Eisai-Biogen’s Supplemental Biologics License Application For Leqembi (Lecanemab-IRMB) 100 mg/ml Injection For Intravenous Use, Supporting The Conversion Of The Accelerated Approval Of Leqembi To A Traditional Approval

By Benzinga Newsdesk

Today, 7:01 PM

The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA is currently planning to hold an Advisory Committee to discuss this application

BIIB

5 minute read

U.S. FDA Broadens Indication For Verzenio In HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

By Happy Mohamed

Today, 7:01 PM

High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade, regardless of Ki-67 score Approval supported by four-year data

LLY